P243 ANXIETY AND DEPRESSION IN ADOLESCENTS AND ADULTS WITH CYSTIC FIBROSIS

doi:10.1136/thoraxjnl-2011-201054c.243

V Fainardi, E Iacinti, F Longo, M C Tripodi, G Pisi. *Center of Cystic Fibrosis, Department of Pediatrics, University Hospital of Parma, Parma, Italy*

Background Little is currently known about the anxiety and depression co-morbidities and Cystic Fibrosis (CF).

Aim To evaluate the association between anxiety and depression and long-term treatment burden in CF patients.

Subjects and Methods In 82 CF patients (36 males, age range 12–44 years, BMI range 15–29 kg/m²), anxiety and depression were assessed by the Hospital Anxiety Depression Scale (HADS). In all patients, spirometry and current therapy, such as scheduled intravenous antibiotics, chronic use of aerosolized antibiotics, insulin therapy, pancreatic enzymes and long-term oxygen therapy, were recorded.

Results A wide range of airflow obstruction was found (FEV₁ range 26–129% pred). 54, 68, 12, 85, and 11 patients underwent intravenous antibiotics, aerosolized antibiotics, insulin therapy, pancreatic enzymes and long-term oxygen therapy, respectively. 33 (40%) and 15 (18%) out of 82 patients were respectively anxious and depressive. Depression was significantly associated with intravenous antibiotics ($p<0.01$, OR 6.0, CI 0.9 to 41) and with long-term oxygen therapy ($p<0.01$, OR 1.4, CI 0.9 to 1.9).

Conclusions The present study shows that use of scheduled intravenous antibiotics and long-term oxygen therapy significantly affect psychological functioning profile in adolescents and adults with CF. Our results further suggest the value of psychological support in CF patients with advanced lung disease.

Acute and chronic respiratory infections

P244 RISK STRATIFICATION OF FLU IN POST-PANDEMIC WINTER 2010

doi:10.1136/thoraxjnl-2011-201054c.244

C M Orton, E Wong, P De, W McAllister. *The Royal Surrey County Hospital, Guildford, UK*

Aims The aim of the study was to review the assessment of acute medical admissions with “Flu like illness” and to identify useful tools in risk-stratifying severity of illness.

Methods This was a retrospective observational study. We reviewed the assessment of all inpatients diagnosed with “flu like illness” from November 2010 to March 2011 at a district general hospital. We evaluated potential risk-stratification tools with respect to adverse outcomes (length of admission and intensive care unit (ITU) admission): Co-morbidities (diabetes mellitus, immunosuppression, pregnancy, chronic respiratory, heart, renal and liver disease), CURB-65 score, C-reactive protein (CRP) and chest x-ray findings (CXR).

Results 27 patients were identified; 6 Male, 19 Female; mean age 40.1. 22 had virology swabs; 12 (62%) were positive for H1N1, 5 (24%) Influenza B and 2 (9%) Influenza A. Length of admission (LOA) ranged from 1 to 30 days (mean 8.3 days). Seven patients required ITU admission. 14 (52%) had no co-morbidities. Six (86%) of seven ITU patients had no co-morbidities. LOA did not differ between patients with co-morbidities and those without (10 vs 10.9 days respectively). 17 (63%) patients had CURB-65 of zero. Five (71%) of seven ITU patients had a CURB-65 of less than three. CURB-65 was poorly correlated with LOA ($R^2=0.22$). CRP on admission ranged from <4 to 511 mmol/l (mean 121 mmol/l). Mean CRP of ITU patients was 240 mmol/l; in contrast to 79 mmol/l in non-ITU cases. CRP was poorly correlated with increased LOA

($R^2=0.16$). 25 patients had CXR on admission and 12 (48%) had abnormal findings. Patients with bilateral CXR changes had a mean LOA of 21 days compared with 3.5 days in those with normal CXR. Six (86%) of seven ITU patients had abnormal CXR.

Conclusion A raised CRP and abnormal CXR findings on admission were associated with adverse outcomes. Co-morbidities and CURB-65 correlated poorly with disease severity. These findings may be explained by the high prevalence of H1N1 influenza in winter 2010. Current Health Protection Agency guidelines place strong emphasis on CURB-65 and co-morbidities in risk-stratification. We recommend the inclusion of CRP on initial assessment and stronger emphasis on CXR changes.

P245 CAN CLINICAL, RADIOLOGICAL OR LABORATORY PARAMETERS DIFFERENTIATE H1N1 ASSOCIATED PNEUMONIA FROM COMMUNITY ACQUIRED PNEUMONIA?

doi:10.1136/thoraxjnl-2011-201054c.245

G E Hayes, C D Sheldon, B D Patel. *Royal Devon and Exeter Hospital, Exeter, UK*

Pneumonia is a recognised complication of H1N1 influenza, and is an important cause of morbidity and mortality. The Department of Health (DoH) identified characteristics that may aid identification of individuals with H1N1 pneumonia (HNP) from those with community acquired pneumonia not associated with H1N1 infection (CAP). These include severe gastrointestinal symptoms, including diarrhoea and vomiting, myalgia, fever $>38^{\circ}\text{C}$, bilateral CXR changes, a low or normal total WCC, tachycardia and a CRP >200 . Lymphopaenia is also reported as a marker of H1N1 infection. This study compared the clinical, physiological and radiological characteristics of patients with HNP with those of patients with CAP to determine if these characteristics can reliably identify those with HNP.

Methods A retrospective case notes review of all patients admitted with CAP or HNP to our institution between December 2010 and February 2011.

Results 16 patients with HNP and 52 patients with CAP were identified. Relative to patients with CAP, those with HNP were significantly younger (mean age 49 yrs ± 22.1 vs 63 yrs ± 23.2 , $p=0.03$), were more likely to present in respiratory failure (92.3% vs 62.5%, $p=0.05$), or with a temperature $>38^{\circ}\text{C}$ (62.5% vs 34.6%, $p=0.05$), and to report vomiting (71.4% vs 23.1%, $p=0.02$). There was no significant difference in reported myalgia (80.0% vs 85.0%), diarrhoea (93.8% vs 79.2%). There was no significant difference in the prevalence of unilateral multilobar consolidation (HNP 25.0% vs CAP 17.3%) or bilateral consolidation (31.3% vs 21.5%). Laboratory results showed no significant difference in lymphocyte count (HNP 0.84 ± 0.47 vs CAP 0.95 ± 0.53), CRP (234.3 ± 204 vs 209.0 ± 129) or neutrophil count (9.5 ± 4.8 vs 12.5 ± 7.5).

Conclusions The features stated in the DoH guidelines do not reliably allow clinical differentiation between HNP and CAP. The presence of vomiting, younger age and high fever are suggestive, but not diagnostic, of HNP and viral PCR remains the gold standard diagnostic tool.

P246 AIRWAY AND SYSTEMIC INFLAMMATION IN STABLE AND EXACERBATED BRONCHIECTASIS: A PILOT STUDY

doi:10.1136/thoraxjnl-2011-201054c.246

R Chitkara, H Batchelor, R J Sapsford, S Workman, A R C Patel, A J Mackay, B Grimbacher, J R Hurst. *UCL Medical School, London, UK*

Introduction It is not known whether systemic inflammation reflects lower airway inflammation in non-CF bronchiectasis. If confirmed,

blood biomarkers may provide useful information on pulmonary disease burden in both stable and exacerbated states. Serum C reactive protein (CRP) is readily measurable in many clinical settings, including at point-of-care, and procalcitonin (PCT) has a potential role with documented utility in other respiratory diseases. This study explored the relationship between airway and systemic inflammatory biomarkers in adult patients with non-CF bronchiectasis.

Method Serum CRP (for systemic inflammation) and PCT, and sputum interleukin (IL)-6 (for airway inflammation) were measured in 31 well-phenotyped stable patients from The London Bronchiectasis Cohort. Six exacerbation samples were obtained from patients who had been previously sampled at baseline, with the exacerbation sample obtained at exacerbation onset, prior to initiation of additional antibiotic therapy. Sputum IL-6 was measured using ELISA, serum PCT using TRACE, and CRP using immunoturbidimetry techniques. Data were analysed using SPSS V.14.0.

Results Of the 31 patients, 23 (74.2%) patients were female, with a mean (SD) age of 54.7 (14.9) years, FEV₁ 2.09 (0.90) l (75.71% predicted), and FVC 3.12 (1.01) l. The predominant aetiologies were primary immunodeficiency (mostly CVID, n=13, 42%), post-infectious (10, 32%) and idiopathic (4, 13%). The median (IQR) baseline sputum IL-6 was 101 (30–701) pg/ml, baseline serum PCT was 0.030 (0.021–0.040) µg/ml and CRP 3.0 (1.0–6.0) mg/l. The degree of systemic inflammation in stable bronchiectasis reflected that occurring in the airways as evidenced by a significant correlation between sputum IL-6 and serum CRP in the 31 stable samples ($r=0.43$, $p=0.027$). There was also a correlation between the two systemic markers (PCT and CRP: $r=0.42$, $p=0.029$), but the relationship between serum PCT and sputum IL-6 concentration was not statistically significant ($r=0.28$, $p=0.127$). In the six patients with paired samples, serum PCT increased significantly from baseline to exacerbation (0.031 vs 0.147 µg/ml $p=0.043$). Changes in sputum IL-6 and blood serum CRP did not reach statistical significance.

Conclusion We report a direct relationship between airway and systemic inflammation in stable patients with non-CF bronchiectasis. This suggests that systemic biomarkers may be useful for monitoring local disease activity in this neglected condition.

P247 THE RESPIRATORY PHENOTYPE OF THE BBS4 NULL MOUSE LUNG

doi:10.1136/thoraxjnl-2011-201054c.247

¹M Cho, ²P Beales, ¹M Hind, ²R Quinlan. ¹Imperial College, London, UK; ²University College London, London, UK

Introduction Bardet–Biedl Syndrome (BBS) is an autosomal recessive disorder due to BBS gene mutations that result in primary ciliary dysfunction (Hildebrandt *et al*, *N Engl J Med* 2011). Primary cilia are found on most eukaryotic cells and have been reported in various human organs including kidneys, brain, and lung airways. BBS patients present with a number of features including polydactyly, obesity, visual impairment and renal cysts and these are also seen in other examples of ciliopathies. Many BBS patients report frequent respiratory infections and are empirically diagnosed with asthma; yet, little is known about the pulmonary effects of BBS and explanations for the respiratory presentations remain unclear. We have recently described the respiratory phenotype of a cohort of 28 consecutive BBS patients (Hind: unpublished data). This study investigates whether there are structural and functional defects in the BBS lung that may explain the frequent respiratory symptoms described by BBS patients.

Methods Lungs from Bbs4 null mice (Bbs4^{−/−}) were examined and compared to unaffected control littermates. Lung volumes were measured by volume displacement and alveolar tissue assessed through morphometry according to ATS/ERS standards (Hsia, *AJRCCM*, 2010). These data were used to derive the alveolar surface area (Sa) for each animal. Functional studies of motile cilia using ciliary beat frequency (CBF) and inflammatory cell types in the distal lungs were analysed both from bronchoalveolar lavage fluid (BALF) and using immunohistochemistry on lung sections.

Results We show that, as seen in the heterogeneous patient group, the Bbs4^{−/−} mice are significantly heavier than control littermates. Lung volume and Sa of all mice increase with age; however, Bbs4^{−/−} mice have smaller lung volumes and a reduced Sa. Furthermore, lung histology demonstrates that Bbs4^{−/−} mice show evidence of chronic infection. Although we have not found any evidence for ultrastructural defects in airway motile cilia, Bbs4^{−/−} null mice have a significantly slower CBF.

Conclusion These data suggest that a loss of function in BBS4 results in a greater body mass, a functional motile ciliary defect, frequent inflammation, and reduced gas-exchanging surface area of the lung.

P248 ASSOCIATIONS OF DEPRESSION, FATIGUE AND QUALITY OF LIFE IN ADULT NON-CF BRONCHIECTASIS

doi:10.1136/thoraxjnl-2011-201054c.248

H Batchelor, S Brill, J S Brown, J R Hurst. *UCL Medical School, London, UK*

Introduction Non-cystic fibrosis bronchiectasis is a chronic lung condition characterised by persistent cough, excessive sputum and recurrent chest infections. Symptoms also include dyspnoea, haemoptysis, depression and fatigue. The latter can have a major impact on patients' physical and psychosocial well-being. We investigated disease- and patient-related factors associated with quality of life, fatigue and depression in bronchiectasis.

Method Patients were recruited from the London Bronchiectasis Cohort. A clinical diagnosis of bronchiectasis was confirmed by review of previous CT imaging. A full medical history including exacerbations and aetiology, spirometry, and the SGRQ (for quality of life), CESD (depression), and FACIT (fatigue) questionnaires were completed at a baseline appointment. Statistics were analysed using SPSS.

Results 31 patients (25 female) were studied with a mean (SD) age of 58.8 (SD 12.0) years. The commonest aetiologies were post-infectious (15/31) and idiopathic (11/31). The median (IQR) self-reported exacerbation frequency was 3.0 (1.9–5.6)/year.

Frequent exacerbations were associated with poorer quality of life: there was a significant association between exacerbation frequency and the SGRQ score ($r=0.46$, $p=0.013$). Frequent exacerbations were also associated with greater baseline breathlessness ($r=0.40$, $p=0.038$), but not with lung function, depression or fatigue. Patients with greater disease severity (lower FEV₁) also had more breathlessness (MRC: $r=-0.38$, $p=0.046$), and poorer quality of life (SGRQ: $r=-0.50$, $p=0.005$) but not greater depression or fatigue. The depression scale was not related to any of the disease or patient-related factors. The only patient or disease-related variable associated with fatigue was breathlessness (MRC: $r=-0.57$, $p=0.002$).

Conclusion The determinants of quality of life, depression and fatigue in non-CF bronchiectasis are different. Depression in this population appears to be independent of markers of disease severity such as FEV₁, exacerbation frequency and MRC dyspnoea score.